Dumont & Blake Investment Advisors LLC Sells 55 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Dumont & Blake Investment Advisors LLC cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 2.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,423 shares of the medical research company’s stock after selling 55 shares during the quarter. Dumont & Blake Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,286,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of TMO. Halpern Financial Inc. lifted its holdings in shares of Thermo Fisher Scientific by 307.7% in the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock worth $27,000 after acquiring an additional 40 shares during the last quarter. Coppell Advisory Solutions LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth about $33,000. Live Oak Investment Partners bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $36,000. Tyler Stone Wealth Management purchased a new stake in Thermo Fisher Scientific in the 2nd quarter valued at about $37,000. Finally, Indiana Trust & Investment Management CO purchased a new position in shares of Thermo Fisher Scientific during the third quarter worth approximately $38,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

TMO stock traded up $1.28 during midday trading on Wednesday, reaching $572.84. The stock had a trading volume of 595,053 shares, compared to its average volume of 1,586,374. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The firm has a fifty day simple moving average of $567.37 and a two-hundred day simple moving average of $522.08. The stock has a market cap of $218.43 billion, a PE ratio of 36.99, a P/E/G ratio of 2.43 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.40 earnings per share. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be paid a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date is Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Analyst Ratings Changes

Several research analysts have commented on TMO shares. Wolfe Research assumed coverage on Thermo Fisher Scientific in a report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price objective on the stock. Raymond James increased their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird reaffirmed an “outperform” rating and issued a $670.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. HSBC started coverage on Thermo Fisher Scientific in a report on Monday, December 18th. They set a “buy” rating and a $610.00 target price for the company. Finally, Royal Bank of Canada upped their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $599.00.

Check Out Our Latest Research Report on Thermo Fisher Scientific

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 in the last three months. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.